SCOPE

Topics Covered

Clinical and Vaccine Immunology (CVI) is devoted to the advancement and dissemination of new knowledge about all aspects of the immune response in health, in disease, and after vaccination. CVI will welcome studies of (i) cellular and humoral immunity in humans and animals; (ii) immunological and immune-mediated disorders, including relevant new animal models for immunologic diseases; (iii) microbial immunology; (iv) viral immunopathogenesis; (v) assay development, standardization, quality control, normal reference values, and biostatistical issues; and (vi) immunoepidemiology.

In addition, the journal will publish articles on all aspects of immunization and vaccine research, including (i) development and evaluation of vaccines; (ii) mechanisms of vaccine action; (iii) the immune response to vaccines in humans and animals; (iv) studies of vaccine vectors, adjuvants, and immunomodulators; (v) immunological correlates of vaccine efficacy; and (vi) clinical trials, including phases 1 through 3.

ASM publishes a number of journals covering various aspects of microbiology. Each journal has a prescribed scope that must be considered in determining where to submit a manuscript. Papers with a primary immunological or vaccine focus are suitable for CVI; those with a primary focus on a microbe, an infectious process, a mechanism of microbial pathogenesis or host response, or animal models for microbial diseases are best directed to one of the other ASM journals. The following guidelines may be of assistance.

1. Papers developing or evaluating animal models for human immune disease and dysfunction are appropriate for CVI; those dealing with development of animal models of microbial pathogenesis should be sent to Infection and Immunity.
2. Papers with a primary focus on the immunology and immunopathogenesis of human viral infections are appropriate for CVI; those using an immunologic approach to basic virology research are more appropriate for the Journal of Virology.
3. Papers that focus on the immunologic aspects of development and evaluation of vaccines in humans and animals, including clinical trials, may be sent to CVI; studies that focus on establishing a proof of principle using nonviral microbial antigens as immunogens or that describe the construction and initial evaluation of novel bacterial vectors are suitable for Infection and Immunity.

Guest Commentaries, intended to raise issues and engender discussion, will occasionally be solicited by the CVI editors.

Questions about these guidelines may be directed to the editor in chief of the journal being considered.

If transfer to another ASM journal is recommended by an editor, the corresponding author will be contacted.

Note that a manuscript rejected by one ASM journal on scientific grounds or on the basis of its general suitability for publication is considered rejected by all other ASM journals.

TOP